written on 17.06.2014

With Pfizer's bid dead, AstraZeneca chief promises eyes on goal


With Pfizer's unwanted buyout bid in the past–at least for now–AstraZeneca needs to cheer up some of its shareholders. After all, some top investors in the U.K.-based drugmaker wanted to cash in on the proposed takeover. So, once again, CEO Pascal Soriot is making his case for AstraZeneca's bright future.